Stock INDV INDIVIOR PLC
Add to a list
To use this feature you must be a member
Log inSign up

Financials Indivior PLC

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 16:35:05 26/04/2024 BST 		5-day change 1st Jan Change
1,408 GBX +0.57% Intraday chart for Indivior PLC -7.00% +18.82%
04-25 Transcript : Indivior PLC, Q1 2024 Earnings Call, Apr 25, 2024
04-25 London-listed Indivior Confirms Plan for Primary Listing in US MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 377.9 1,091 2,441 3,057 2,060 2,375 - -
Enterprise Value (EV) 1 -443.1 518.3 1,581 2,523 1,983 2,148 1,876 1,539
P/E ratio 2.87 x -7.44 x 12.9 x -58.9 x 1,508 x 9.43 x 7.24 x 5.55 x
Yield - - - - - - - -
Capitalization / Revenue 0.48 x 1.69 x 3.09 x 3.39 x 1.88 x 1.87 x 1.67 x 1.51 x
EV / Revenue -0.56 x 0.8 x 2 x 2.8 x 1.81 x 1.69 x 1.32 x 0.98 x
EV / EBITDA -2 x 4.89 x 7.83 x 11.2 x 6.88 x 5.74 x 4.14 x 2.79 x
EV / FCF -2.97 x -2.63 x 4.67 x -11.1 x -4.8 x 8.58 x 6.71 x 3.25 x
FCF Yield -33.6% -38% 21.4% -9% -20.8% 11.6% 14.9% 30.8%
Price to Book - - - 61.1 x - 10.5 x 3.92 x 2.23 x
Nbr of stocks (in thousands) 146,153 146,701 140,437 136,489 136,551 135,438 - -
Reference price 2 2.586 7.439 17.38 22.40 15.08 17.54 17.54 17.54
Announcement Date 13/02/20 18/02/21 16/02/22 16/02/23 22/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 785 647 791 901 1,093 1,273 1,419 1,573
EBITDA 1 222 106 202 225 288 374.5 453.3 552
EBIT 1 202 88 187 212 269 351.5 422 522.8
Operating Margin 25.73% 13.6% 23.64% 23.53% 24.61% 27.62% 29.74% 33.23%
Earnings before Tax (EBT) 1 180 -173 190 -95 1 332 407.2 543
Net income 1 134 -148 205 -53 2 267.8 341.2 439.8
Net margin 17.07% -22.87% 25.92% -5.88% 0.18% 21.04% 24.04% 27.96%
EPS 2 0.9000 -1.000 1.350 -0.3800 0.0100 1.860 2.423 3.160
Free Cash Flow 1 149 -197 339 -227 -413 250.2 279.4 473.8
FCF margin 18.98% -30.45% 42.86% -25.19% -37.79% 19.66% 19.69% 30.12%
FCF Conversion (EBITDA) 67.12% - 167.82% - - 66.82% 61.64% 85.84%
FCF Conversion (Net income) 111.19% - 165.37% - - 93.45% 81.89% 107.73%
Dividend per Share 2 - - - - - - - -
Announcement Date 13/02/20 18/02/21 16/02/22 16/02/23 22/02/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 222 - 221 253 276 271 293 284 305.6 328.2 344.4 358.8 362.5
EBITDA 1 - - - - - - - 77 78 98.5 112.9 112.5 109
EBIT 1 32 - - 71 71 60 66 70 78 93.75 105 107.5 107
Operating Margin 14.41% - - 28.06% 25.72% 22.14% 22.53% 24.65% 25.52% 28.57% 30.47% 29.96% 29.52%
Earnings before Tax (EBT) 1 - - - - 62 -181 61 63 75.6 91.35 102.6 101.9 101.4
Net income 1 - 41 - 44 39 -135 54 47 58.65 70.55 79.6 78.4 78.1
Net margin - - - 17.39% 14.13% -49.82% 18.43% 16.55% 19.19% 21.5% 23.11% 21.85% 21.54%
EPS 2 - 0.3000 - 0.3100 - -0.9800 0.3800 0.3400 0.4250 0.5200 0.5850 0.5800 0.5800
Dividend per Share - - - - - - - - - - - - -
Announcement Date 16/02/22 28/04/22 28/07/22 27/04/23 27/07/23 09/11/23 22/02/24 25/04/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 821 573 860 534 77 227 499 836
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 149 -197 339 -227 -413 250 279 474
ROE (net income / shareholders' equity) - - - 133% 875% 274% 91.4% 55.3%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - 0.3700 - 1.670 4.470 7.880
Cash Flow per Share - - - - - - - -
Capex 1 7 4 14 5 8 7 24.7 9.6
Capex / Sales 0.89% 0.62% 1.77% 0.55% 0.73% 0.55% 1.74% 0.61%
Announcement Date 13/02/20 18/02/21 16/02/22 16/02/23 22/02/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Indivior PLC

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.54 USD
Average target price
31.03 USD
Spread / Average Target
+76.93%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
INDIVIOR PLC Stock Indivior PLC
+18.82% 2.38B
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.90% 1.65B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. INDV Stock
  4. Financials Indivior PLC